THE LACNETS PODCAST
Episode 6: Decision-Making for NETs
ABOUT THIS EPISODE:
How do NET experts decide what treatments are right for you? How do I learn about current clinical trials? In our sixth episode, NET expert and medical oncologist Dr. Daneng (Dan) Li of City of Hope answers 10 common questions about decision-making for NETs including finding the primary tumor site, bone mets, tumor grades, and the role of adjuvant therapy.
MEET DR. DANENG (DAN) LI
Daneng Li, M.D., is an assistant professor in the Department of Medical Oncology & Therapeutics Research at City of Hope, specializing in treating gastrointestinal cancers. Dr. Li currently leads the liver tumors program and is also the co-director of the Neuroendocrine Tumor Program at City of Hope.
Dr. Li earned his undergraduate degree from The Ohio State University in Columbus, Ohio, graduating summa cum laude. He then went on to receive his medical doctorate from Weill Cornell Medical College in New York, before pursuing an internship and residency in internal medicine at New York-Presbyterian Hospital/Weill Cornell Medical Center. He then completed a hematology/oncology fellowship at Memorial Sloan-Kettering Cancer Center in New York City.
Board certified in internal medicine and medical oncology, Dr. Li serves on several national committees focused on his specialty tumor types. He has authored several publications in the peer reviewed literature, and has presented his work nationally.
TOP 10 QUESTIONS
1. How important is it to find the primary tumor site? How much effort should go into pursuing this? How common is it to have a NET with an unknown primary site?
2. What do you do when someone who has been diagnosed with NET has elevated tumor markers and symptoms but scans show no evidence of disease?
3. What’s the difference between a functional and nonfunctional NET?
4. How are bone mets treated?
5. How concerned would you be with a patient’s bone marrow during PRRT treatment especially if they have bone lesions?
6. Do tumor grades ever change?
7. When would you recommend doing another biopsy?
8. What is the role of adjuvant therapy for NET?
9. When do YOU consider clinical trials for NET patients?
10. How do patients or advocates find out about clinical trials and decide if that’s the best option for them?